A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

The University of Rochester’s Flaum Eye Institute is embedding behavioral health into ophthalmology to improve patient care ...

Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...

Chemical injuries to the ocular surface can be challenging to manage because they lie at the intersection of urgency and long-term consequences. The severity of these injuries dep ...

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

In unilateral intermittent exotropia, distance control improved significantly over 3 months of therapy (mean 2.9 to 1.7; ...